Corcept Therapeutics announced that its Phase III ROSELLA study evaluating relacorilant in combination with nab-paclitaxel in platinum-resistant ovarian cancer successfully met its primary overall survival endpoint. The trial demonstrated a 35% reduction in the risk of death versus nab-paclitaxel monotherapy, with median overall survival extended to 16.0 months compared with 11.9 months for the control arm. The safety profile of the combination was consistent with expectations for nab-paclitaxel, and no new safety signals were observed.

Following the positive ROSELLA results, H.C. Wainwright analyst Swayampakula Ramakanth upgraded Corcept’s rating to Buy and raised the price target from $90 to $105, implying a potential upside of approximately 46.8%. This marks the second upward revision this quarter, reflecting growing confidence in the relacorilant franchise and its potential to address an unmet need in platinum-resistant ovarian cancer.

Shares of Corcept saw a significant uptick in trading volume, surpassing three million shares exchanged on the day of the announcement. This surge reflects heightened investor interest following the trial news and analyst upgrade. Market capitalization now stands near $4.4 billion, positioning Corcept among mid-cap oncology-focused biopharmaceutical names drawing attention for late-stage clinical catalysts.

Corcept operates in a competitive field that includes established generic and specialty players such as Teva Pharmaceuticals and Mylan, which also target cortisol-related and oncologic indications. The company plans to submit full ROSELLA data to regulators by mid-year and engage in discussions regarding accelerated approval pathways. Additional analyses of quality-of-life measures and subgroup survival data are expected to be presented at a major oncology conference in the third quarter.